Rudolph Navari on Preventing CINV With Olanzapine

Article

Rudolph Navari, discusses a study of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.

Rudolph Navari, director, Cancer Care Program in Central and South America, World Health Organization, professor of medicine, Indiana University School of Medicine-South Bend, discusses a study of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content